CHINTYA NUGRAHINI, - (2024) POTENSI ASAM KLOROGENAT DARI KOPI SEBAGAI TERAPI DIABETES MELITUS TIPE 2 MELALUI UJI IN VITRO TERHADAP ENZIM AMILASE PANKREATIN. Skripsi thesis, Sekolah Tinggi Farmasi Indonesia.
Text
S_PSSF_A201071_Title.pdf Download (615kB) |
|
Text
S_PSSF_A201071_Chapter1.pdf Restricted to Repository staff only Download (59kB) |
|
Text
S_PSSF_A201071_Chapter2.pdf Restricted to Repository staff only Download (291kB) |
|
Text
S_PSSF_A201071_Chapter3.pdf Restricted to Repository staff only Download (160kB) |
|
Text
S_PSSF_A201071_Chapter4.pdf Restricted to Repository staff only Download (189kB) |
|
Text
S_PSSF_A201071_Chapter5.pdf Restricted to Repository staff only Download (78kB) |
|
Text
S_PSSF_A201071_Appendix.pdf Restricted to Repository staff only Download (659kB) |
Abstract
Diabetes Melitus tipe 2 merupakan gangguan metabolik yang ditandai oleh peningkatan kadar glukosa darah akibat resistensi insulin. Asam klorogenat (CGA) senyawa bioaktif yang banyak ditemukan dalam kopi, memiliki potensi sebagai penghambat enzim α-amilase pankreatin, yang dapat membantu mengurangi penyerapan glukosa dari karbohidrat. Penelitian ini bertujuan untuk mengevaluasi aktivitas penghambatan CGA terhadap enzim pankreatin sebagai alternatif pengobatan diabetes melitus tipe 2. Uji aktivitas penghambatan enzim dilakukan menggunakan enzim pankreatin dan substrat pati, dengan berbagai konsentrasi CGA dari ekstrak kopi Arabika dan Robusta. Uji penghambatan enzim dilakukan menggunakan metode spektrofotometri untuk mengukur kandungan CGA dalam kopi. Hasil penelitian menunjukkan bahwa ekstraksi dengan metode shaker pada kopi Arabika menghasilkan kadar CGA tertinggi sebesar 26,179%, diikuti oleh kopi Robusta dengan 20,794%, dan kopi Arabika dengan metode maserasi sebesar 13,615%. Pada metode shaker, kandungan CGA yang lebih tinggi menunjukkan potensi penghambatan enzim α-amilase dengan nilai inhibisi sebesar 26,559%, diikuti oleh kopi Robusta (24,909%), kopi Arabika maserasi (4,605%), CGA 50% (19,257%), dan CGA 100% (2,274%). Hasil ini menunjukkan bahwa ekstrak kopi Arabika metode shaker memiliki potensi sebagai kandidat terapi alami dalam pengelolaan diabetes melitus tipe 2. ----- Type 2 diabetes mellitus is a metabolic disorder characterized by elevated blood glucose levels due to insulin resistance. Chlorogenic acid (CGA), a bioactive compound widely found in coffee, has potential as an inhibitor of the α-amylase enzyme pancreatin, which can help reduce glucose uptake from carbohydrates. This study aims to evaluate the inhibitory activity of CGA against pancreatin enzyme as an alternative treatment for type 2 diabetes mellitus. Enzyme inhibition activity test was conducted using pancreatin enzyme and starch substrate, with various concentrations of chlorogenic acid from Arabica and Robusta coffee extracts. Enzyme inhibition test was conducted using spectrophotometric method to measure CGA content in coffee. The results showed that extraction with the shaker method on Arabica coffee produced the highest CGA content of 26.79%, followed by Robusta coffee with 20.94%, and Arabica coffee with maceration method with 13.615%. In the shaker method, the higher CGA content showed the potential inhibition of α-amylase enzyme with an inhibition value of 26.559%, followed by Robusta coffee (24.910%), macerated Arabica coffee (4.605%), 50% CGA (19.258%), and 100% CGA (2.274%). These results suggest that shaker method Arabica coffee extract has potential as a natural therapeutic candidate in the management of type 2 diabetes mellitus.
Item Type: | Thesis (Skripsi) |
---|---|
Uncontrolled Keywords: | Diabetes melitus tipe 2, Asam klorogenat (CGA), Kopi Arabika, Kopi Robusta, Enzim α-amilase. ---- Type 2 diabetes mellitus, Chlorogenic acid (CGA), Arabica Coffee, Robusta Coffee, α-amylase |
Subjects: | Q Science > Q Science (General) R Medicine > R Medicine (General) |
Divisions: | Program Studi S1 Farmasi |
Depositing User: | pustakawan - - |
Date Deposited: | 12 Nov 2024 08:34 |
Last Modified: | 12 Nov 2024 08:34 |
URI: | http://repository.stfi.ac.id/id/eprint/1469 |
Actions (login required)
View Item |